BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37810797)

  • 1. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
    Celik A; Berg T; Jensen MB; Jakobsen E; Nielsen HM; Kümler I; Glavicic V; Jensen JD; Knoop A
    Breast Cancer (Auckl); 2023; 17():11782234231203292. PubMed ID: 37810797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.
    Kim H; Kim HJ; Kim H; Kim HR; Jo H; Hong J; Kim R; Kim JY; Ahn JS; Im YH; Lee SK; Kim H; Shin SY; Park YH
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
    Grinda T; Antoine A; Jacot W; Cottu PH; de la Motte Rouge T; Frenel JS; Mailliez A; Dalenc F; Goncalves A; Clatot F; Mouret Reynier MA; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Arnedos M; Chevrot M; Courtinard C; Tredan O; Brain E; Pérol D; Pistilli B; Delaloge S
    Eur J Cancer; 2023 Aug; 189():112935. PubMed ID: 37385070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices.
    Tan R; Cassoli L; Yan Y; Shen V; Day BM; Mitchell EP
    Front Public Health; 2022; 10():859113. PubMed ID: 35685754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
    Srimuninnimit V; Pornpraserthsuk P; Chaiwerawattana A; Kongdan Y; Namkanisorn T; Somwangprasert A; Jatuparisuthi C; Puttawibul P; Vongsaisuwan M; Thongthieang L; Bandidwattanawong C; Tantimongkolsuk C
    PLoS One; 2018; 13(12):e0209040. PubMed ID: 30566471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
    Bianco N; Milano M; Pagan E; Oriecuia C; Bagnardi V; Rocco EG; Santomauro GI; Peruzzotti G; Colleoni M; Viale G
    Breast Cancer Res Treat; 2022 Jan; 191(1):137-145. PubMed ID: 34609640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark.
    Garly R; Berg T; Jensen MB; Knoop A; Volmer L; Glavicic V; Khan H; Poulsen PB; Olsen J; Kümler I
    Acta Oncol; 2023 Mar; 62(3):290-297. PubMed ID: 37010239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.
    Hsu JY; Chang CJ; Cheng JS
    Sci Rep; 2022 Jan; 12(1):729. PubMed ID: 35031634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Objective response of first-line chemotherapy of triple-negative breast cancer translates into survival benefit: an analysis in an independent, prospective clinical trial and a real-world setting.
    Li T; Zhu YH; Zhang J; Wang BY; Zhang S; Wang LP; Cao J; Tao ZH; Xie J; Hu XC
    Neoplasma; 2020 Nov; 67(6):1400-1408. PubMed ID: 32657608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier.
    Chung WP; Yang CT; Chen HY; Su CY; Su HW; Ou HT
    J Formos Med Assoc; 2022 Jan; 121(1 Pt 2):319-328. PubMed ID: 34006465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
    Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V;
    Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
    Chen Y; Guan Y; Wang J; Ma F; Luo Y; Chen S; Zhang P; Li Q; Cai R; Li Q; Mo H; Lan B; Chen X; Zhao W; Xu B; Fan Y
    Int J Cancer; 2020 Dec; 147(12):3490-3499. PubMed ID: 32588429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy.
    W DeClue R; Fisher MD; Gooden K; Walker MS; Le TK
    Future Oncol; 2023 Apr; 19(13):909-923. PubMed ID: 37191097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
    Chabot I; Zhao Q; Su Y
    Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.
    Müller V; Ruhnke M; Hoffmann O; Grafe A; Tomé O; Fett W; Bruch HR; Sommer-Joos AK; Schneeweiss A
    Breast; 2021 Dec; 60():70-77. PubMed ID: 34488065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.
    Mougalian SS; Kish JK; Zhang J; Liassou D; Feinberg BA
    Adv Ther; 2021 May; 38(5):2213-2225. PubMed ID: 33491157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine.
    Zhu Y; Li K; Zhang J; Wang L; Sheng L; Yan L
    Transl Cancer Res; 2021 Mar; 10(3):1193-1203. PubMed ID: 35116447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
    Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.